Implications of the FINE-ONE Trial

Name: Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Uploaded: 2025-11-08T05:00:00+00:00
Description: Chronic kidney disease (CKD) occurs in 1 of 3 people with type 1 diabetes. Over half of these individuals develop substantial loss of kidney function

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- prof. Hiddo Heerspink
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
Diabetes
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
- Femke Rutters, MD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD

Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?

Recommended

Title

Share on ReachMD